PRODUCTSNEXLETOL^®, NEXLIZET^®

NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) are oral, non-statin therapies FDA approved to lower low density lipoprotein cholesterol (LDL-C) and reduce the risk of myocardial infarction and coronary revascularization in patients who unable to take recommended statin therapy or need more LDL-C lowering than a statin alone can provide. The products, which act upstream of statins, were initially FDA approved in February 2020 and subsequently received expanded indications in March 2024 to include cardiovascular risk reduction and LDL-C lowering in both primary and secondary prevention patients.

Background

HealthCare Royalty and Athyrium Capital Management collectively provided Esperion Therapeutics with a credit facility of $150 million (with HealthCare Royalty contributing $50 million). The credit facility was part of a broader refinancing of a portion of outstanding obligations under the company’s $265 million in 4.00% Convertible Senior Subordinated Notes due November 2025.